Big Pharmas Back $300m Neglected Disease Fund
Cash For Projects 'Wall Street and Silicon Valley Pay Little Attention To'
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
